Kong Qian, Li Ping, Tian Qiong, Ha Min-Wen
1 Department of Oncology, The First Affiliated Hospital of Liaoning Medical University , Jinzhou, People's Republic of China .
Genet Test Mol Biomarkers. 2014 May;18(5):357-65. doi: 10.1089/gtmb.2013.0506. Epub 2014 Mar 27.
This meta-analysis was performed to evaluate the relationships of a common polymorphism (T309G, rs2279744 T>G) in the murine double minute 2 (MDM2) gene with susceptibility and prognosis of nonsmall cell lung cancer (NSCLC).
The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or hazard risk (HR) with their 95% confidence intervals (95% CI) were calculated. Seven clinical studies with a total 3732 NSCLC patients and 1472 healthy controls met the inclusion criteria.
The results of our meta-analysis suggested that MDM2 T309G polymorphism might be strongly correlated with an increased risk of NSCLC (G allele vs. T allele: OR=1.63, 95% CI: 1.42-1.89, p<0.001; TG+GG vs. TT: OR=1.54, 95% CI: 1.31-1.80, p<0.001; respectively). Furthermore, we observed significant associations of MDM2 T309G polymorphism with poor overall survival (TT vs. GT: HR=1.22, 95% CI: 101-1.43, p<0.001; TT vs. GG: HR=1.31, 95% CI: 1.04-1.59, p<0.001; TT vs. GT+GG: HR=1.44, 95% CI: 1.13-1.76, p<0.001; respectively) and progression-free survival (TT vs. GT+GG: HR=1.26, 95% CI: 0.82-1.69, p<0.001) of NSCLC patients.
Our findings provide convincing evidence that the MDM2 T309G polymorphism may contribute to individual differences in NSCLC susceptibility and prognosis. Thus, the MDM2 T309G polymorphism may be a promising potential biomarker for NSCLC diagnosis and prognosis.
本荟萃分析旨在评估鼠双微体2（MDM2）基因常见多态性（T309G，rs2279744 T>G）与非小细胞肺癌（NSCLC）易感性及预后的关系。
检索PubMed、CISCOM、CINAHL、Web of Science、谷歌学术、EBSCO、Cochrane图书馆和中国生物医学文献数据库，查找2013年11月1日前发表的相关文章，无语言限制。使用STATA 12.0软件进行荟萃分析。计算粗比值比（OR）或风险比（HR）及其95%置信区间（95%CI）。七项临床研究共纳入3732例NSCLC患者和1472例健康对照，符合纳入标准。
我们的荟萃分析结果表明，MDM2 T309G多态性可能与NSCLC风险增加密切相关（G等位基因与T等位基因：OR = 1.63，95%CI：1.42 - 1.89，p < 0.001；TG + GG与TT：OR = 1.54，95%CI：1.31 - 1.80，p < 0.001）。此外，我们观察到MDM2 T309G多态性与NSCLC患者总生存期较差（TT与GT：HR = 1.22，95%CI：1.01 - 1.43，p < 0.001；TT与GG：HR = 1.31，95%CI：1.04 - 1.59，p < 0.001；TT与GT + GG：HR = 1.44，95%CI：1.13 - 1.76，p < 0.001）及无进展生存期（TT与GT + GG：HR = 1.26，95%CI：0.82 - 1.69，p < 0.001）显著相关。
我们的研究结果提供了令人信服的证据，表明MDM2 T309G多态性可能导致NSCLC易感性和预后的个体差异。因此，MDM2 T309G多态性可能是NSCLC诊断和预后的一个有前景的潜在生物标志物。
